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Hypertriglyceridemia is the most prevalent lipid alteration
in end-stage renal disease, and we studied the relationship
between serum triglycerides and all-cause and cardiovascular
death in these patients. Since abdominal fat modifies the
effect of lipids on atherosclerosis, we analyzed the interaction
between serum lipids and waist circumference (WC) as a
metric of abdominal obesity. In a cohort of 537 hemodialysis
patients, 182 died, 113 from cardiovascular causes, over
an average follow-up of 29 months. In Cox models that
included traditional and nontraditional risk factors, there
were significant strong interactions between triglycerides
and WC to both all-cause and cardiovascular death. A fixed
(50mg/dl) excess in triglycerides was associated with a
progressive lower risk of all-cause and cardiovascular
mortality in patients with threshold WC o95 cm but with
a progressive increased risk in those above this threshold.
A significant interaction between cholesterol and WC with
all-cause and cardiovascular death emerged only in
models excluding the triglycerides–WC interaction. Neither
high-density lipoprotein (HDL) nor non-HDL cholesterol or
their interaction terms with WC were associated with study
outcomes. Thus, the predictive value of triglycerides and
cholesterol for survival and atherosclerotic complications
in hemodialysis patients is critically dependent on WC.
Hence, intervention studies in end-stage renal disease
should specifically target patients with abdominal obesity
and hyperlipidemia.
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Anthropometric measures of abdominal obesity like waist
circumference (WC) and waist/hip ratio have consistently
emerged as direct predictors of all-cause and cardiovascular
(CV) mortality in disparate populations, including the
general population,1 patients with CV disease, or with
chronic kidney disease.2 Recently, we reported that WC is a
direct, strong predictor of death and incident CV events in
end-stage renal disease (ESRD) patients in analyses, adjusting
for the body mass index (BMI) and other risk factors,3 and
proposed that this metric be added to standard risk factors
for refining risk stratification in this population. This study
helped to dissect the differential contribution to adverse
clinical outcomes of segmental fat accumulation from that
of BMI, which is an established, inverse predictor of clinical
events in the same population. Besides BMI, serum
cholesterol is also inversely related to survival in dialysis
patients.4–6 Similarly, hypertriglyceridemia, the most pre-
valent alteration of the lipid profile in patients with renal
insufficiency,7 was an inverse predictor of mortality in a
study in male veterans with stage 3–5 chronic kidney disease.8
Until now, there are only two studies investigating the
relationship between triglycerides and clinical outcomes
in dialysis patients. In the first study in patients on peritoneal
dialysis,9 serum triglycerides resulted a direct predictor of
death, whereas in the second study in hemodialysis (HD)
patients,10 a U-shaped relationship was reported.
Recent observations indicate that nutrition status and
body built represent important effect modifiers for the
relationship between lipids and clinical outcomes in
ESRD. Cholesterol was a direct death predictor in non-
malnourished, noninflamed patients, but an inverse one in
those with evidence of malnutrition–inflammation in a
study by Liu et al.11 Similarly, this lipid was directly
associated with mortality in African Americans,10 a popula-
tion with much denser lean body mass than Caucasians,12 but
was inversely related with the same outcome in other
ethnicities. Therefore, it is important that observational
studies in ESRD investigating the effect of lipids on clinical
outcomes carefully consider effect modification by para-
meters of nutritional status. Such studies appear of particular
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relevance after the Deutsche Diabetes Dialyse Studie13 and
Assessment of Survival and Cardiovascular Events,14 the two
trials that documented an overall lack of protective effect of
atorvastatin and rosuvastin on survival and CV events in
dialysis patients.
Abdominal fat is the major reservoir of lipids, and
observations in the general population indicate that this
fundamental parameter of body built modifies the effect
of lipids on atherosclerosis and clinical events. Abdominal
obesity interacts with serum lipids in accelerating the
progression rate of atherosclerosis in men.15 Similarly, in
elderly individuals with large WC, high-density lipoprotein
(HDL) cholesterol loses its protective effect against ischemic
stroke.16 Furthermore, regional differences in adiposity
may have diverse implications on clinical outcomes in HD
patients.17
With this background in mind, we have now performed
interaction analyses of WC with serum triglycerides and
cholesterol as related to all-cause and CV mortality in the
original study cohort, wherein we had tested the prognostic
power of WC and waist hip ratio in HD patients.
RESULTS
The study cohort (n¼ 537) was similar to the whole,
contemporary dialysis population (n¼ 1143) treated in the
Calabrian Region as for age (63 vs 62 years), sex (males: 58 vs
57%), diabetes (16 vs 19%), blood pressure (137±22/75±12
vs 139±20/78±11mmHg), causes of renal disease, and
background comorbidities. The main demographic, somato-
metric, and clinical characteristics of the whole study
population and in patients as grouped according to tertiles
of WC are detailed in Table 1. In all, 41 patients were
taking statins and 18 were on polyunsaturated omega-3
fatty acids supplements. In the whole study population,
serum cholesterol (158±40mg/dl) and serum triglycerides
(166±96mg/dl) were above the corresponding upper limit
of the normal range (serum cholesterol: 200mg/dl; serum
triglycerides: 150mg/dl) in 66 (12%) and in 275 (51%)
HD patients, respectively. Patients in the third WC tertile
were significantly older, more frequently diabetic, displayed
higher BMI, triglycerides, cholesterol, and C-reactive protein,
and had lower dialysis vintage, fractional urea clearance (urea
clearance time/volume) (Kt/V), and HDL cholesterol when
compared with those in the second and in the first WC
tertiles (Table 1). On univariate analysis, serum cholesterol
and triglycerides were inter-related (r¼ 0.56, Po0.001),
directly associated with BMI, WC, hip circumference,
hemoglobin, and use of statins/polyunsaturated omega-3
fatty acids supplements, and inversely related to male sex
(Table 1). Serum cholesterol was inversely related to smoking,
whereas triglycerides were directly related to diabetes and
inversely to age and Kt/V.
Serum triglycerides and cholesterol, all-cause, and CV death
During the follow-up period (average: 29 months, range 1–47
months), 182 patients died, 113 of them of CV causes.
Table 1 |Main clinical, hemodynamic, and biochemical characteristics of the study population
Waist circumference tertiles Correlation analyses
Whole
group
I tertile
(o88 cm)
II tertile
(88–99 cm)
III tertile
(499 cm)
P for
trend
Cholesterol
vs
Triglycerides
vs
Age (years) 63±15 60±18 63±13 66±12 o0.001 0.006 (0.89) 0.11 (0.01)
Male sex (%) 58% 51% 63% 59% 0.13 0.21 (o0.001) 0.09 (0.04)
Dialysis vintage (months) 48 (19–97) 58 (20–116) 48 (19–88) 44 (19–87) 0.02 0.04 (0.37) 0.07 (0.13)
Kt/V 1.36±0.27 1.40±0.7 1.37±0.26 1.32±0.24 0.006 0.04 (0.36) 0.12 (0.02)
Smokers (%) 11% 15% 14% 8% 0.08 0.11 (0.02) 0.07 (0.12)
Diabetics (%) 16% 6% 16% 28% o0.001 0.04 (0.41) 0.12 (0.009)
Patients with CV comorbidities (%) 27% 26% 27% 28% 0.65 0.03 (0.56) 0.02 (0.62)
On antihypertensive treatment (%) 49% 56% 52% 57% 0.83 0.05 (0.30) 0.05 (0.25)
On treatment with statins/polyunsaturated
omega-3 fatty acids supplements (%)
10% 10% 11% 11% 0.83 0.10 (0.04) 0.22 (o0.001)
BMI (kg/m2) 25.1±4.5 21.9±2.9 25.1±3.1 28.7±4.4 o0.001 0.22 (o0.001) 0.29 (o0.001)
Waist circumference (cm) 93.0±13.3 79.2±8.5 94.0±3.1 107.0±8.3 o0.001 0.16 (0.001) 0.26 (o0.001)
Waist/hip ratio 0.93±0.10 0.88±0.10 0.95±0.07 0.99±0.09 o0.001 0.06 (0.20) 0.05 (0.31)
Systolic pressure (mmHg) 137±22 138±23 135±21 137±22 0.86 0.04 (0.44) 0.05 (0.26)
Diastolic pressure (mmHg) 75±12 76±12 74±12 75±11 0.42 0.02 (0.70) 0.06 (0.22)
Pulse pressure (mmHg) 62±17 62±17 61±17 62±17 0.94 0.03 (0.54) 0.04 (0.43)
Heart rate (beats/min) 75±15 75±16 73±14 77±14 0.24 0.07 (0.16) 0.03 (0.51)
Triglycerides (mg/dl) 140 (91–215) 116 (85–172) 142 (99–192) 177 (96–266) o0.001 0.56 (o0.001) —
Total cholesterol (mg/dl) 158±44 149±39 160±46 165±46 0.002 — 0.56 (o0.001)
HDL cholesterol (mg/dl) 35±12 37±12 36±14 33±10 0.002 0.01 (0.77) 0.21 (o0.001)
Non-HDL cholesterol (mg/dl) 122±42 114±38 124±44 130±42 0.57 0.96 (o0.001) 0.60 (o0.001)
Calciumphosphate (mg2/dl2) 45±20 46±20 44±19 43±21 0.11 0.07 (0.15) 0.02 (0.73)
Hemoglobin (g/dl) 11±2 11±2 11±2 10±2 0.29 0.12 (0.01) 0.11 (0.01)
CRP (mg/l) 4.7 (2.0–11.7) 3.8 (1.5–9.4) 4.2 (1.9–11.9) 6.5 (3.0–16.1) o0.001 0.08 (0.07) 0.05 (0.31)
Abbreviations: BMI, body mass index; CRP, C-reactive protein; CV, cardiovascular; HDL, high-density lipoprotein; Kt/V, fractional urea clearance (urea clearance time/volume).
Data are mean±s.d., median and interquartile range, or as percent frequency, as appropriate. In the last two columns the correlation coefficients of cholesterol and
triglycerides with all risk factors listed in the table are also reported.
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Triglycerides, total cholesterol, HDL cholesterol, and low-
density lipoprotein (LDL) cholesterol failed to predict both
all-cause and CV mortality (P¼NS). However, there was a
direct relationship between BMI-adjusted serum triglycerides
and the incidence rate of all-cause and CV death in patients
in the third WC tertile and an opposite trend in those in the
lower two WC tertiles (Figure 1), pointing to an interaction
between these two predictor variables for predicting all-cause
(P¼ 0.04) and CV mortality (P¼ 0.03). Accordingly, in a
Cox model adjusting for all potential confounders and
dialysis vintage, a highly significant interaction emerged
between triglycerides with WC for predicting both all-cause
(Po0.001) and CV death (P¼ 0.002; Table 2). An interaction
between cholesterol and WC materialized only in a model
excluding the triglycerides–WC interaction (P¼ 0.02 and
P¼ 0.01, respectively), suggesting that these lipid compounds
are in the same pathway conducive to adverse clinical
events in HD patients with large WC. Forcing gender into
these models did not affect these results (all-cause mortality:
WC triglycerides interaction, Po0.001; WC cholesterol
interaction, P¼ 0.025; CV mortality: WC triglycerides
interaction, P¼ 0.003; WC cholesterol interaction, P¼
0.015) and resulted to be unrelated to study outcomes
(P¼NS). Neither HDL cholesterol nor non-HDL cholesterol
nor their interaction terms with WC were associated with
study outcomes (P¼NS). As shown in Figure 2, the estimated
hazard ratio of serum triglycerides approached neutrality
(HRB1) when the WC was 95 cm. A fixed (50mg/dl) excess
in triglycerides was associated with a gradual decrease in the
risk of all-cause and CV mortality at progressively lower levels
of WC in patients with a WC o95 cm, but with an opposite
effect in those with WC 495 cm. Similar relationships were
observed for cholesterol in models excluding the triglyce-
ridesWC interaction (Figure 3). Sensitivity analyses exclud-
ing an outlier (WC: 172 cm; triglycerides: 418mg/dl; total
cholesterol: 175mg/dl) showed very similar results (all-cause
mortality: WC triglycerides interaction, P¼ 0.003; WC
cholesterol interaction, P¼ 0.046; CV mortality: WC tri-
glycerides interaction, P¼ 0.001; WC cholesterol interaction,
P¼ 0.012). Forcing into Cox models the remaining risk factors
listed in Table 1 did not materially affect the strength of these
relationships. No interaction existed between triglycerides or
cholesterol with use of statins/polyunsaturated omega-3 fatty
acids supplements for predicting all-cause and CV mortality.
In Figures 4 and 5, the interaction analyses of serum lipids
with abdominal obesity are also reported in probabilistic terms
according to tertiles of WC. In these categorical analyses,
progressively higher levels of triglycerides and cholesterol
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Figure 1 | Incidence rate of all-cause and cardiovascular
mortality throughout triglyceride levels separately in patients
in the third (gray circles) and in the first/second (white circles)
waist circumference tertiles (see Results section for more
details).
Table 2 |Multiple Cox regression analysis of waist
circumference triglycerides interaction for predicting
(a) all-cause and (b) CV mortality
Hazard ratio, 95% CI,
and P-value
(a)
Waist circumference triglycerides
interaction (controlled for the main effect
of triglycerides and waist circumference)
See Figure 2 (P for
interaction o0.001)
BMI (1 kg/m2) 0.88 (0.83–0.93), Po0.001
Age (1 year) 1.06 (1.05–1.08), Po0.001
Smoking (0=no; 1=yes) 0.92 (0.55–1.56), P=0.77
Diabetes (0=no; 1=yes) 2.88 (2.00–4.13), Po0.001
Hemoglobin (1 g/dl) 0.89 (0.81–0.99), P=0.02
Dialysis vintage (10 months) 1.03 (1.01–1.05), P=0.02
(b)
Waist circumference triglycerides
interaction (controlled for the main effect
of triglycerides and waist circumference)
See Figure 2 (P for
interaction=0.002)
BMI (1 kg/m2) 0.85 (0.80–0.92), Po0.001
Age (1 year) 1.07 (1.05–1.09), Po0.001
Smoking (0=no; 1=yes) 0.79 (0.39–1.64), P=0.53
Diabetes (0=no; 1=yes) 2.92 (1.84–4.65), Po0.001
Systolic pressure (20mmHg) 1.15 (0.96–1.38), P=0.14
Kt/V 0.57 (0.24–1.37), P=0.21
On treatment with statins/polyunsaturated
omega-3 fatty acids supplements
(0=no; 1=yes)
2.00 (1.10–3.65), P=0.02
Dialysis vintage (10 months) 1.02 (0.99–1.05), P=0.21
Abbreviations: BMI, body mass index; CI, confidence interval; CV, cardiovascular;
Kt/V, fractional urea clearance (urea clearance time/volume).
Data are expressed as hazard ratio, 95% CI, and P-value. The effect of serum
triglycerides of the risk of all-cause and CV mortality across waist circumference
values is fully presented in both relative (Figure 2) and probabilistic terms (Figure 4)
(see Statistical Analysis in Materials and Methods for more details).
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had opposite associations with clinical outcomes in the first
(increasing risk at lower WC) and in the third (increasing risk
at higher WC) tertiles of WC, whereas in the middle tertile
neither triglycerides nor cholesterol levels did affect the risk
of all-cause and CV death (Figures 4 and 5, middle panels).
The interactions between BMI with triglycerides and
cholesterol for all-cause and CV death were weaker or not
significant when compared with those between WC and
serum lipids.
DISCUSSION
This study shows that WC represents an effect modifier for
triglycerides as related to death and fatal CV events in dialysis
patients. Serum cholesterol shows the same effect modifica-
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Figure 2 |Hazard ratios (HRs) and 95% confidence intervals for all-cause and cardiovascular mortality of a fixed (50mg/dl) excess
in serum triglycerides across waist circumference values. As shown in the figure, the HR of serum triglycerides was neutral (HRB1)
when the waist circumference was 95 cm. Furthermore, a fixed (50mg/dl) excess in triglycerides was associated with a gradual decrease
in the risk of all-cause and cardiovascular (CV) mortality at progressively lower levels of waist circumference in patients with a waist
circumference o95 cm but with an opposite effect in those with waist circumference 495. The HRs were adjusted for the full set of
variables listed in Table 2. The effect modification of waist circumference on the prognostic effect of serum triglycerides was also
almost identical after the exclusion of the outlier (waist circumference: 172 cm; triglycerides: 418mg/dl; total cholesterol: 175mg/dl;
see Results section for more details).
All-cause mortality Cardiovascular mortality
7 7 (8.9)
6 6
55
4 4
H
az
ar
d 
ra
tio
(50
 m
g/d
l e
xc
es
s i
n s
eru
m 
ch
ole
ste
rol
)
3 3 100
2 2
80
60 (n)
1 1 40
20Outlier Outlier
0 0 0
Waist circumference Waist circumference
(cm) (cm)
17214012511095806550 17214012511095806550
Figure 3 |Hazard ratios (HRs) and 95% confidence intervals for all-cause and cardiovascular mortality of a fixed (50mg/dl) excess
in serum cholesterol across waist circumference values. As shown in the figure, the hazard ratio of serum cholesterol was neutral
(HRB1) when the waist circumference was 95 cm. Furthermore, a fixed (50mg/dl) excess in cholesterol was associated with a gradual
decrease in the risk of all-cause and CV mortality at progressively lower levels of waist circumference in patients with a waist circumference
o95 cm, but with an opposite effect in those with waist circumference 495 cm. The HRs were adjusted for all potential confounders
(all-cause mortality model: cholesterol, waist circumference, cholesterol/waist circumference interaction term, body mass index (BMI), age,
smoking, diabetes, hemoglobin, dialysis vintage, and C-reactive protein (CRP); cardiovascular (CV) mortality model: cholesterol, waist
circumference, cholesterol/waist circumference interaction term, BMI, age, smoking, diabetes, fractional urea clearance (urea
clearance time/volume), dialysis vintage, treatment with statins/polyunsaturated omega-3 fatty acids supplements, and CRP). The effect
modification of waist circumference on the prognostic effect of serum cholesterol was also almost identical after the exclusion of the outlier
(waist circumference: 172 cm; triglycerides: 418mg/dl; total cholesterol: 175mg/dl; see Results section for more details).
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tion that materializes only in statistical models excluding
the triglycerides–WC interaction.
Malnutrition and inflammation are exceedingly prevalent
in ESRD.18 Because of the pervasiveness of these conditions,
cholesterol is either normal or low in dialysis patients,
a derangement that makes this biomarker an inverse,
rather than a direct predictor of mortality.19 This inverse
epidemiology has been invoked as a likely explanation of why
recent randomized clinical trials with lipid-lowering drugs
did not show a benefit in dialysis patients.13,14
Hypertriglyceridemia is a hallmark of insulin resistance
and a cardinal element for the definition of metabolic
syndrome.20 Consistent biological evidence supports a poten-
tial role for triglycerides as a vascular risk factor,20 but
the issue of whether triglycerides represent an independent
risk factor at community level is still an open question.
A comprehensive meta-analysis in western populations
showed a continuous graded influence of fasting and
nonfasting triglycerides on coronary heart disease incidence
that extended down into the normal range and remained
significant after adjustment for LDL and HDL cholesterol
and other risk factors.21 However, a recent, updated meta-
analysis failed to confirm an independent role of triglycerides
in CV risk.21 In ESRD, a condition with a peculiar risk factor
profile that differs substantially from that in the general
population,22 only two studies investigated the association
between triglycerides and survival. In the first study, focusing
on patients treated by peritoneal dialysis, triglycerides were
directly associated with death risk,9 whereas in the second
study in HD patients, the relationship was U shaped.10
The WHO (World Health Organization) formally recom-
mends WC and waist/hip ratio to estimate the health burden
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Figure 4 | Estimated probabilities of all-cause and
cardiovascular (CV) death associated with progressively
higher values of serum triglycerides according to waist
circumference tertiles. These probabilities were calculated by
using the regression coefficients of Cox regression analyses,
adjusting for all variables listed in Table 2. In these categorical
analyses, progressively higher levels of triglycerides had opposite
associations with clinical outcomes in the first (increasing risk at
lower waist circumference) and in the third (increasing risk at
higher waist circumference) tertile of waist circumference. In the
middle waist circumference tertile, a progressive increase in
triglycerides levels did not affect the risk of all-cause and CV
death. The gray area identifies the 95% confidence intervals of
estimated probabilities.
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Figure 5 | Estimated probabilities of all-cause and
cardiovascular (CV) death associated with progressively
higher values of serum cholesterol according to waist
circumference tertiles. These probabilities were calculated by
using the regression coefficients of Cox regression analyses,
adjusting for all potential confounders (see legend to Figure 2).
In these categorical analyses, progressively higher levels of
cholesterol had opposite associations with clinical outcomes in
the first (increasing risk at lower waist circumference) and in the
third (increasing risk at higher waist circumference) tertile of waist
circumference. In the middle waist circumference tertile, a
progressive increase in cholesterol levels did not affect the risk
of all-cause and CV death. The gray area identifies the 95%
confidence intervals of estimated probabilities.
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posed by obesity at the community level.23 Obesity appears to
be an expanding problem in the dialysis population and
recent data indicate that WC provides important prognostic
information in this population.3 Present analyses further
highlight the potential relevance of considering this metric in
epidemiologic studies in ESRD. Although we did not find
clearcut associations between cholesterol and triglycerides,
HDL and non-HDL cholesterol, and clinical outcomes, WC
emerged as a modifier for the relationship of triglycerides
with both all-cause and CV death. In other words, the risk
associated with exposure to a fixed (50mg/dl) excess in
serum triglycerides was associated with a gradual decline in
the risk of overall and CV mortality at progressively lower
WC values in patients with WC o95 cm, whereas an
opposite relationship was evident in patients with WC
495 cm (effect modification of triglycerides by WC). A
similar effect modification also emerged for cholesterol, but
only in analyses excluding the triglycerides–WC interaction
from the statistical models. Neither HDL cholesterol nor
non-HDL cholesterol nor their interaction terms with WC
were associated with clinical outcomes, indicating that it is
much unlikely that these lipid fractions are confounders for
the triglycerides–WC interaction. Furthermore, the inter-
actions between BMI with triglycerides and cholesterol for
all-cause and CV death were weaker or not significant when
compared with those between WC and serum lipids.
Triglycerides are lipids preferentially synthesized when the
calorie intake is high, which serve to meet immediate energy
needs in muscles or to store fatty acids for future energy
requirements. The fact that in our study a triglyceride excess
signaled a lower death risk in patients with low WC accords
with the interpretation that high levels of lipids represent a
proxy of adequate intake of nutrients and relatively better
overall health status in dialysis patients. On the other hand,
the opposite relationship in patients with large WC is in
keeping with findings in the metabolic syndrome, a condition
characterized by abdominal obesity where high triglycerides
denote a high risk for atherosclerotic complications.20 It
appears likely that the metabolic milieu of uremia, per se
characterized by inflammation, endothelial dysfunction, and
a prothrombotic propensity, further amplifies the risk
captured by serum triglycerides in patients with central
obesity, which is per se a proinflammatory, prothrombotic
condition.20 Our additional finding that the cholesterol–WC
interaction emerged only in models excluding the triglycer-
ides–WC interaction is biologically compatible with the role
that triglyceride-rich lipoprotein remnants have in trapping
small dense LDL cholesterol particles into the arterial wall,24
a phenomenon that poses triglycerides and cholesterol into
the same pathway conducive to arterial damage. Our data
should be looked at globally, as a continuous phenomenon
occurring across the whole spectrum of WC. Indeed, on one
hand, an excess in plasma triglycerides denoted a progressively
reduced risk for death and fatal CVevents in patients with low
WC and, on other hand, an identical triglyceride excess
denoted a progressively increased risk for the same outcomes.
This interaction suggests that hypertriglyceridemia should
not be regarded as a treatment target in ESRD patients with
low WC, whereas correction of this alteration may be useful
in those with large WC, an issue that may be settled only by a
specific clinical trial. Obesity is an expanding problem in the
dialysis population in most countries. Trials in the sub-
population with abdominal obesity would be a worthy
undertaking. Post hoc analyses of a large trial with statins in
patients with cardiac ischemia showed that achievement of
low triglyceride levels on therapy is associated with a well-
defined decrease in the risk of CV events.25 Omega-3
polyunsaturated fatty acids had no effect on CV events but
reduced the incidence of myocardial infarction in a relatively
small trial with a high drop-out rate in dialysis patients.26
Post hoc analyses in Deutsche Diabetes Dialyse Studie13 and
Assessment of Survival and Cardiovascular Events14 may
specifically explore the issue in ESRD patients and enlarge the
knowledge basis for planning future, well-targeted studies
with lipid-lowering drugs in ESRD patients.
In conclusion, the predictive value of triglycerides for
survival and fatal atherosclerotic complications in ESRD
patients appears critically dependent on WC. A triglyceride
excess entails a favorable prognosis in individuals without
abdominal obesity, but signals a risk excess for all-cause and
CV death in those with abdominal obesity. Overall, these
findings generate the hypothesis that interventions on serum
lipids in dialysis patients with large WC may translate into
favorable clinical outcomes in this population.
MATERIALS AND METHODS
The protocol was in conformity with the ethical guidelines of our
institution, and as we used standard, anonymous, registry data, no
written informed consent was requested from participants.
Study population
This study is based on the dialysis registry of a southern
Italian Region (Calabria REgistry of DIalysis and Transplantation
(CREDIT)) affiliated with the Italian and the ERA-EDTA Registries.
CREDIT includes anonymous data of all patient with ESRD treated in
36 dialysis units of the same region. Collected data are those requested
by the National and European registries and additional data on
comorbidities and other data driven by specific research projects of the
regional registry. A total of 24 centers (that is, 67%) participated in this
study, and 537 patients were enrolled in this study. No patient refused
participation. Thus, enrolled patients represent all eligible for this
study. The main characteristics of the study population are given in
Table 1. Our study population is an incident-prevalent cohort of 537
HD patients, a sample representative (sampling fraction ofB50%) of
the whole HD population included in the Calabrian Registry of
Dialysis, the vast majority of whom were functionally anuric. On
average, Kt/V in this population was 1.34±0.26. The large majority of
patients (91%) were treated thrice weekly with standard bicarbonate
dialysis (Na 138mmol/l, HCO3 35mmol/l, K 1.5mmol/l, Ca
1.25mmol/l, and Mg 0.75mmol/l) either by cuprophan or semisyn-
thetic membranes (dialysis filters surface area: 1.1–1.7m2), and
approximately one-half (49%) were on antihypertensive treatment.
Only a minority of patients were treated by hemodiafiltration (3%) or
other extracorporeal treatments (6%).
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Study design and baseline data collection
The demographic, clinical, and anthropometric data of all patients
treated with extracorporeal dialysis in participating centers were
obtained between June and December 2003. For the purpose of this
study, anthropometric data (height, weight, and waist and hip
measurements) were collected in participating centers. Waist and
hip circumferences were measured with a nonstretchable standard
tape measure. WC was measured over the unclothed abdomen at
the midpoint of the lower thoracic cage and the iliac crest in the
mid-axillary line, and hip circumference was measured at the level
of the widest diameter around the buttocks, as recommended by the
WHO.27 Both weight and height were measured with standardized
protocols. BMI was calculated as weight in kg divided by height
in m2. Serum C-reactive protein was measured by a high-sensitivity
immunoturbidimetric method (high-sensitivity C-reactive protein;
Dade Behering, Marburg, Germany) in a central laboratory.
Fasting cholesterol, triglycerides, and phosphate were measured by
standard methods implemented in multichannel analyzers in hospital
laboratories of participant centers. These laboratories adhered to
national or regional quality control programs, and bias of cholesterol
and triglyceride measurements was below ±5%, with intra- and
inter-assay coefficients of variation o6 and 8%, respectively. Predia-
lysis arterial pressure and heart rate were measured three times after a
10-min resting period while seated, and the average value of these
measurements was considered in the statistical analysis. All measure-
ments were obtained midweek before dialysis.
Follow-up
All patients were followed up until December 2006 or censoring
(study end, kidney transplantation, or lost to observation). Primary
kidney disease and causes of death were classified according to the
coding system of the European Renal Association-European Dialysis
and Transplantation Association (http://www.srr.scot.nhs.uk/ERA_
EDTA/ERA_EDTA_PRD_Codes_Deaths.pdf).
Statistical analysis
Data are reported as mean±s.d., median and interquartile range, or
as percent frequency, as appropriate. The association between paired
variables was tested using Pearson’s product moment correlation
coefficient (r) and P-value. Variables having a positively skewed
distribution were log transformed (lg10) before the correlation study.
The detection of outliers was performed using Grubb’s test.28
The interaction analyses between serum lipids and WC for
predicting all-cause and CV mortality were investigated by Cox’s
regression by simultaneously including into the multiple regression
models triglycerides, WC, and triglyceridesWC (triglyceride-based
models), and cholesterol, WC, and cholesterolWC (cholesterol-
based models). The effect modification of WC on the risk of clinical
outcomes associated with serum triglycerides and cholesterol is
presented in both relative and absolute terms by (1) plotting the
hazard ratio for all-cause and CV death of a constant increase
(50mg/dl) in serum lipids across the whole range of WC values
(Figures 2 and 3), and (2) plotting the probability of all-cause and
CV death associated with progressively higher levels of triglycerides
and cholesterol according to WC tertiles (Figures 4 and 5). Details
about the calculation of hazard ratios of all-cause and CV death
associated with serum lipids according to WC values are given in the
legends to Figures 2 and 3 and in Appendix. We focused on these
interactions because they emerged as significant predictors of study
outcomes at univariate Cox’s regression. Neither HDL cholesterol
nor non-HDL cholesterol nor their interaction terms with WC were
associated with study outcomes, and therefore these measurements
were excluded from multivariate models. Multivariate models
adjusted for all variables that met the criteria to be confounders,
that is, variables (1) that were related (Po0.20) with both exposures
(triglyceridesWC and cholesterolWC interaction terms) and
study outcomes (all-cause and CV mortality); (2) that were not an
effect of exposures, and (3) that were not in the causal pathway
between the exposures and study outcomes. In these models, we
always forced dialysis vintage. Besides lipids, tested variables
included Framingham risk factors (age, sex, smoking, and diabetes
and systolic pressure), BMI, CV comorbidities, factors peculiar to
ESRD (serum phosphate, hemoglobin, dialysis vintage, and Kt/V),
treatment with statins/polyunsaturated omega-3 fatty acids supple-
ments, and C-reactive protein. The estimated probabilities of all-
cause and CV death (and 95% confidence interval) associated with
serum lipids and WC tertiles were calculated by using the equations
derived from multiple Cox regression analyses reported in Table 2.
In these equations, all terms, except triglycerides/cholesterol and
WC, were set to the corresponding average value. Data are expressed
as hazard ratios and their 95% confidence intervals. All calculations
were done using a standard statistical package (STATA 9 for
Windows, College Station, TX).
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Appendix
Calculation of the hazard ratio for death of a fixed excess
(50mg/dl) in serum triglycerides across waist circumference
values
Multiple Cox regression analysis of waist circumfer-
ence triglycerides interaction for predicting all-cause mortal-
ity (see table below). For illustrative purpose, only regression
coefficients are reported (the corresponding hazard ratios are
given in Table 2).
A significant interaction between triglycerides and waist
circumference (WC) (Po0.001) implies that the hazard
ratio for mortality of a fixed excess in triglycerides (50mg/dl)
must be calculated at prespecified values of WC by
combining the corresponding regression coefficients derived
from Cox regression analysis. For example, the hazard
ratios for mortality of the same (50mg/dl) excess in
triglycerides at WC values of 65 and 110 cm are calculated
as follows:
Hazard ratio of 50mg=dl increase in triglyceridesðWC¼65Þ ¼
2:71830:77753þ0:0080165 ¼ 0:78
Hazard ratio of 50mg=dl increase in triglyceridesðWC¼110Þ ¼
2:71830:77753þ0:00801110 ¼ 1:11
As a consequence of the effect modification of WC on the risk
of death related to serum triglycerides, a fixed excess in
triglycerides (50mg/dl) is associated with a risk reduction
(hazard ratio=0.78, relative risk reduction=0.22 or 22%)
in patients with relatively low WC (65 cm) and with a risk
increase (hazard ratio=1.11, relative risk increase=0.11 or
11%) in those with relatively high WC (110 cm). For more
details about the hazard ratio calculation in the presence of
multiplicative interaction, see Kleinbaum and Klein.29
Regression coefficients
Waist circumference triglycerides
(1 cm 50mg/dl)
0.00804*
Waist circumference (1 cm) 0.00441
Serum triglycerides (50mg/dl) 0.77753
Body mass index (1 kg/m2) 0.13227
Age (1 year) 0.06202
Smoking (0=no; 1=yes) 0.07820
Diabetes (0=no; 1=yes) 1.05791
Hemoglobin (1 g/dl) 0.11379
Dialysis vintage (10 months) 0.02599
*Po0.001.
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